# AbCellera

> AbCellera is a VC fund in Vancouver backing Biopharma and Veterinary. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Vancouver, Canada
- Total investments: 2
- Last investment: Sep 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/abcellera/
- X (Twitter): https://www.twitter.com/abcellerabio
- Website: https://www.abcellera.com/

AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner.With the integrated AbCellera platform, our experts search a wide range of diverseantibodies to select the most effective and developable leads fast and set our partners up for enduring success.  We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

## Contacts

5 contacts available for AbCellera. Shizune tracks 9 team members at AbCellera. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/abcellera-biologics?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Veterinary | 1 | 50% |
| Biotechnology | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Booth | Chief Financial Officer | 1 | — |
| Anne Stevens | Head of Business Partnering | 0 | — |
| Bryan Barnhart | Scientific Director | 0 | — |
| Carl Hansen | President | 2 | — |
| Jake Beverage | Vice President, Alliance Management | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Invetx | Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $10.3M | Series A | Sep 30, 2020 |  |
| Invetx | Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $15M | Series A | Feb 24, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Anterra Capital](https://shizune.co/investors/profile/anterra-capital) — VC Fund, 2 deals together
- WuXi Biologics — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 1 deal together
- [Tekla Capital Management](https://shizune.co/investors/profile/tekla-capital-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does AbCellera invest in?

AbCellera invests primarily in Biopharma, Veterinary and Biotechnology startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact AbCellera?

Public channels for AbCellera include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at AbCellera?

The team at AbCellera includes Andrew Booth (Chief Financial Officer), Anne Stevens (Head of Business Partnering) and Bryan Barnhart (Scientific Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co